EDAP Reports Strong Second Quarter 2025 HIFU Results
EDAP TMS SA (NASDAQ: EDAP) reported strong Q2 2025 results, highlighted by exceptional growth in its core HIFU business. The company achieved 76.8% year-over-year HIFU revenue growth to EUR 8.5 million, driven by nine Focal One system sales versus three in Q2 2024. Total revenue reached EUR 16.0 million, up 1.6% year-over-year.
Key developments include a 36 million Euro credit facility letter of intent with the European Investment Bank and increased 2025 HIFU revenue growth guidance to 26-34% from previous 16-25%. The company reported a Q2 2025 net loss of EUR 5.6 million (EUR 0.15 per share), improved from EUR 6.1 million loss in Q2 2024.
EDAP's strategic focus on its high-margin HIFU business resulted in improved gross margins of 42.5% in Q2 2025, up from 37.5% in Q2 2024, while the company continues planned reduction of non-core ESWL and Distribution operations.
EDAP TMS SA (NASDAQ: EDAP) ha riportato risultati solidi nel secondo trimestre 2025, con una crescita eccezionale nel suo core business HIFU. I ricavi HIFU sono aumentati del 76,8% su base annua, arrivando a EUR 8,5 milioni, sostenuti dalla vendita di nove sistemi Focal One rispetto a tre nel secondo trimestre 2024. Il fatturato totale ha raggiunto EUR 16,0 milioni, in crescita dell'1,6% su base annua.
Tra gli sviluppi principali figura una lettera d'intenti per una linea di credito di 36 milioni di euro con la Banca Europea per gli Investimenti e la revisione al rialzo della guidance 2025 per la crescita dei ricavi HIFU, ora prevista tra il 26% e il 34% rispetto al precedente 16-25%. La societ脿 ha registrato una perdita netta di EUR 5,6 milioni (EUR 0,15 per azione) nel Q2 2025, migliorata rispetto alla perdita di EUR 6,1 milioni nel Q2 2024.
La focalizzazione strategica di EDAP sul business HIFU ad alta marginalit脿 ha portato a un miglioramento del margine lordo, salito al 42,5% nel Q2 2025 rispetto al 37,5% dello stesso periodo del 2024, mentre continua la riduzione pianificata delle attivit脿 non core ESWL e di distribuzione.
EDAP TMS SA (NASDAQ: EDAP) anunci贸 s贸lidos resultados en el segundo trimestre de 2025, destacando un crecimiento excepcional en su negocio principal HIFU. Los ingresos por HIFU crecieron un 76,8% interanual hasta EUR 8,5 millones, impulsados por la venta de nueve sistemas Focal One frente a tres en el Q2 de 2024. Los ingresos totales alcanzaron EUR 16,0 millones, un 1,6% m谩s interanual.
Entre los hitos clave figura una carta de intenci贸n para una l铆nea de cr茅dito de 36 millones de euros con el Banco Europeo de Inversiones y la subida de la previsi贸n de crecimiento de ingresos HIFU para 2025 al 26-34% desde el anterior 16-25%. La compa帽铆a registr贸 una p茅rdida neta en el Q2 2025 de EUR 5,6 millones (EUR 0,15 por acci贸n), mejorando frente a la p茅rdida de EUR 6,1 millones en el Q2 2024.
El enfoque estrat茅gico de EDAP en su negocio HIFU de alto margen se tradujo en una mejora del margen bruto, alcanzando el 42,5% en el Q2 2025 frente al 37,5% del Q2 2024, mientras la empresa sigue reduciendo de forma planificada las operaciones no core de ESWL y distribuci贸n.
EDAP TMS SA (NASDAQ: EDAP)電� 2025雲� 2攵勱赴 臧曤牓頃� 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 頃奠嫭 HIFU 靷梾鞚� 鞓堨櫢鞝� 靹膘灔鞚� 霊愲摐霟鞀惦媹雼�. HIFU 毵れ稖鞚� 鞝勲厔 雽�牍� 76.8% 歃濌皜頃橃棳 850毵� 鞙犽毳� 旮半頄堨溂氅�, 鞚措姅 2024雲� 2攵勱赴 3雽�鞐愳劀 9雽�鞚� Focal One 鞁滌姢韰� 韺愲Г鞐� 旮办澑頃╇媹雼�. 齑濍Г於滌潃 1600毵� 鞙犽搿� 鞝勲厔 霃欔赴 雽�牍� 1.6% 歃濌皜頄堨姷雼堧嫟.
欤检殧 靷暛鞙茧電� 鞙犽熃韴瀽鞚�頄�(EIB)瓿检潣 3,600毵� 鞙犽 鞁犾毄鞁滌劋鞐� 雽�頃� 鞚橅枼靹� 觳搓舶瓿� 2025雲� HIFU 毵れ稖 靹膘灔 臧�鞚措崢鞀るゼ 旮办〈 16-25%鞐愳劀 26-34%搿� 靸來枼 臁办爼頃� 鞝愳澊 韽暔霅╇媹雼�. 須岇偓電� 2025雲� 2攵勱赴 靾滌啇鞁れ澊 560毵� 鞙犽(欤茧嫻 0.15鞙犽)搿� 氤搓碃霅橃棃鞙茧┌, 鞚措姅 2024雲� 2攵勱赴 靾滌啇鞁� 610毵� 鞙犽鞐愳劀 臧滌劆霅� 靾橃箻鞛呺媹雼�.
EDAP臧� 瓿犽歆� HIFU 靷梾鞐� 鞝勲灥鞝侅溂搿� 歆戩頃� 瓴瓣臣, 2025雲� 2攵勱赴 齑濎澊鞚惦鞚� 42.5%搿� 2024雲� 2攵勱赴鞚� 37.5%鞐愳劀 臧滌劆霅橃棃瓿�, 牍勴暤鞁� ESWL 氚� 鞙犿喌 靷梾鞚� 瓿勴殟霅� 於曥唽霃� 歆�靻嶍晿瓿� 鞛堨姷雼堧嫟.
EDAP TMS SA (NASDAQ: EDAP) a publi茅 de solides r茅sultats pour le deuxi猫me trimestre 2025, marqu茅s par une croissance exceptionnelle de son activit茅 HIFU principale. Les revenus HIFU ont augment茅 de 76,8% en glissement annuel 脿 8,5 M鈧� , port茅s par la vente de neuf syst猫mes Focal One contre trois au T2 2024. Le chiffre d'affaires total s'est 茅lev茅 脿 16,0 M鈧�, en hausse de 1,6% sur un an.
Parmi les faits marquants figure une lettre d'intention pour une facilit茅 de cr茅dit de 36 millions d'euros avec la Banque europ茅enne d'investissement et le rel猫vement des pr茅visions de croissance des revenus HIFU pour 2025 脿 26-34% (contre 16-25% auparavant). La soci茅t茅 a enregistr茅 une perte nette de 5,6 M鈧� au T2 2025 (0,15 鈧� par action), en am茅lioration par rapport 脿 la perte de 6,1 M鈧� au T2 2024.
La focalisation strat茅gique d'EDAP sur son activit茅 HIFU 脿 forte marge a entra卯n茅 une am茅lioration de la marge brute, 脿 42,5% au T2 2025 contre 37,5% au T2 2024, tandis que la r茅duction planifi茅e des activit茅s non strat茅giques ESWL et de distribution se poursuit.
EDAP TMS SA (NASDAQ: EDAP) meldete starke Ergebnisse f眉r das 2. Quartal 2025, wobei das Kernsegment HIFU au脽ergew枚hnlich wuchs. Die HIFU-Ums盲tze stiegen jahr眉berjahr um 76,8% auf EUR 8,5 Mio., getragen von neun verkauften Focal One-Systemen gegen眉ber drei im Q2 2024. Der Gesamtumsatz belief sich auf EUR 16,0 Mio., ein Anstieg von 1,6% gegen眉ber dem Vorjahr.
Wesentliche Entwicklungen umfassen eine Absichtserkl盲rung 眉ber eine Kreditlinie in H枚he von 36 Mio. Euro mit der Europ盲ischen Investitionsbank und die Anhebung der Umsatzwachstumsprognose f眉r HIFU 2025 auf 26鈥�34% (zuvor 16鈥�25%). Das Unternehmen verzeichnete im Q2 2025 einen Nettoverlust von EUR 5,6 Mio. (EUR 0,15 je Aktie), eine Verbesserung gegen眉ber dem Verlust von EUR 6,1 Mio. im Q2 2024.
EDAPs strategische Fokussierung auf das margenstarke HIFU-Gesch盲ft f眉hrte zu einer Verbesserung der Bruttomarge auf 42,5% im Q2 2025 gegen眉ber 37,5% im Q2 2024, w盲hrend die geplante Reduzierung der nicht zum Kerngesch盲ft geh枚renden ESWL- und Vertriebsaktivit盲ten fortgesetzt wird.
- HIFU revenue grew 76.8% year-over-year to EUR 8.5 million
- Secured 36 million Euro credit facility letter of intent with EIB
- Increased 2025 HIFU revenue growth guidance to 26-34%
- Improved gross margin to 42.5% from 37.5% year-over-year
- Placed 12 Focal One systems, representing 140% net placement growth
- 23.9% growth in worldwide disposable revenue
- Reduced net loss to EUR 5.6 million from EUR 6.1 million year-over-year
- Operating expenses increased to EUR 12.6 million from EUR 12.1 million
- Cash position decreased to EUR 16.3 million from EUR 22.8 million in Q1
- Non-core business revenue declined 30.9% to EUR 7.6 million
- First half 2025 net loss increased to EUR 12.7 million from EUR 10.7 million year-over-year
Insights
EDAP's core HIFU business shows remarkable 76.8% YoY growth with strong Focal One system placements, despite overall modest total revenue growth.
EDAP's Q2 2025 results demonstrate a strategic pivot in action with impressive growth in their core HIFU business segment alongside a planned decline in non-core operations. The
The company's decision to focus on their high-margin HIFU business is clearly paying off with gross profit margins expanding to
The
Despite the strong operational momentum, the company continues to operate at a loss with Q2 operating losses at
EDAP's Focal One HIFU system is gaining significant clinical adoption, supported by robust clinical evidence and strategic expansion into new indications.
The
The
The announced EIB credit facility points toward strategic expansion beyond current applications. Management specifically mentions "new indications and further development of focused ultrasound technologies" as investment targets. This suggests EDAP is planning to leverage its core HIFU technology platform beyond prostate cancer into additional clinical applications, potentially expanding their addressable market.
The upcoming launch of the new Focal One i Robotic HIFU System indicates continued innovation in the platform. For medical technologies, iterative platform improvements are essential for maintaining competitive advantage and expanding clinical utility. While details on the enhancements in this new system aren't provided, the timing alongside increasing clinical evidence suggests EDAP is coordinating product development with market education efforts - a strategy that typically accelerates adoption in medical technology markets.
- +
140% Focal One庐 Net Placement Growth Year over Year - +
76.8% HIFU Revenue Growth Year over Year - 36 million Euro Credit Facility Letter of Intent Executed with European Investment Bank (EIB) to further accelerate HIFU Growth and Strategic Expansion
- Company raises 2025 HIFU Year over Year Revenue Growth Guidance range to
26% to34% , up from the prior range of16% to25%
听Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT
听AUSTIN, Texas, August 28, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2025.
鈥淲e experienced our strongest second quarter performance in our company鈥檚 history, placing a net total of 12 Focal One Robotic HIFU Systems with increased customer demand coming from both U.S. and international markets,鈥� said Ryan Rhodes, Chief Executive Officer. 鈥淭he strong year over year growth in the second quarter underscores the accelerating momentum of our leading Focal One platform and its increased adoption amongst urologists. To continue to advance the expansion of Focal One, including new indications and further development of focused ultrasound technologies, we executed a letter of intent with the European Investment Bank that will provide a significant source of low interest rate capital. As we enter the second half of 2025, our Focal One pipeline continues to strengthen, and we anticipate demand for Focal One continuing to grow as more prostate cancer patients recognize the advantages of the Focal One treatment. This momentum is further supported by the groundbreaking publication from the large multicenter prospective comparative HIFI study and the compelling Level 1 clinical evidence from the FARP Randomized Controlled Trial, both of which are gaining wider dissemination within the global urology community.鈥�
Business Update
- On August 26, 2025, the Company announced a letter of intent for credit facility with the European Investment Bank (EIB) for 36 million Euros
- On July 1, 2025, the Company announced that, effective January 1, 2026, EDAP will become a U.S. domestic filer and will begin complying with corresponding U.S. SEC reporting rules and Nasdaq listing requirements
- On April 29, 2025, the Company announced that the positive final 3-year outcomes of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) were presented at the 120th AUA Annual Meeting
- On April 24, 2025, the Company announced the launch of the new Focal One i Robotic HIFU System
Upcoming Meetings and Events
EDAP management will attend and present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference, in New York City from September 8-10, 2025. The Company is scheduled to present on September 9th from 8:30AM - 9:00AM ET and will also conduct 1x1 investor meetings. Click to register for the EDAP webcast.
2025 Financial Guidance
The Company is updating its 2025 financial guidance. Core HIFU business revenue is now expected to grow within the range of
Second Quarter 2025 Results
Total revenue in the HIFU business for the second quarter of 2025 was EUR 8.5 million (USD 9.7 million), as compared to EUR 4.8 million (USD 5.2 million) for the second quarter of 2024, representing growth of +
Total revenue in the Company鈥檚 non-core business (ESWL and Distribution) for the second quarter of 2025 was EUR 7.6 million (USD 8.7 million), as compared to EUR 11.0 (USD 11.8 million) for the second quarter of 2024. The decline in non-core business revenue was expected based on the Company鈥檚 strategic decision to focus exclusively on the high growth opportunity in focal therapy with the Focal One Robotic HIFU platform.
Total worldwide revenue for the second quarter of 2025 was EUR 16.0 million (USD 18.4 million), an increase of
Gross profit for the second quarter of 2025 was EUR 6.8 million (USD 7.8 million), compared to gross profit of EUR 5.9 million (USD 6.4 million) for the year-ago period. Gross profit margin on net sales was
Operating expenses were EUR 12.6 million (USD 14.5 million) for the second quarter, compared to EUR 12.1 million (USD 13.0 million) for the same period in 2024. The increase in operating expenses was primarily due to focused investments in our HIFU business.
Operating loss for the second quarter of 2025 was EUR 5.8 million (USD 6.6 million), compared to an operating loss of EUR 6.1 million (USD 6.6 million) in the second quarter of 2024.
Net loss for the second quarter of 2025 was EUR 5.6 million (USD 6.4 million), or EUR (0.15) per share, as compared to net loss of EUR 6.1 million (USD 6.6 million), or EUR (0.16) per share in the second quarter of 2024.
First Half 2025 Results
Total revenue in the HIFU business for the six months ended June 30, 2025, was EUR 14.7 million (USD 16.1 million), an increase of
Total revenue in the Company鈥檚 non-core business (ESWL and Distribution) business for the six months ended June 30, 2025, was EUR 15.0 million (USD 16.5 million), a
Total worldwide revenue for the six months ended June 30, 2025, was EUR 29.6 million (USD 32.6 million), a decrease of
Gross profit for the six months ended June 30, 2025, was EUR 12.5 million (USD 13.8 million), compared to EUR 12.3 million (USD 13.3 million), for the six months ended June 30, 2024. Gross profit margin on net sales was
Operating expenses were EUR 24.3 million (USD 26.7 million) for the six months ended June 30, 2025, compared to EUR 23.3 million (USD 25.1 million) for the same period in 2024.
Operating loss for the six months ended June 30, 2025, was EUR 11.8 million (USD 13.0 million), compared to an operating loss of EUR 11.0 million (USD 11.8 million) for the six months ended June 30, 2024.
Net loss for the six months ended June 30, 2025, was EUR 12.7 million (USD 14.0 million), or EUR (0.34) per share, as compared to a net loss of EUR 10.7 million (USD 11.5 million), or EUR (0.29) per share for the six months ended June 30, 2024.
As of June 30, 2025, the Company held cash and cash equivalents of EUR 16.3 million (USD 19.1 million) as compared to EUR 22.8 million (USD 24.6 million) as of March 31, 2025.
Conference Call Information
A conference call and webcast to discuss the second quarter 2025 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and Fran莽ois Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Date:听听听听听听听听听听听听听听听听听听听听听听听听Thursday, August 28th @ 8:30am Eastern Time
Domestic: 听 听 听 听 听 听 听 听 听1-800-274-8461
International: 听 听 听 听 听 听 听1-203-518-9814
Passcode (Conf ID):听 听 EDAP 听听听听听 听听听听听听听听
Webcast:听听听听听听听听 听听听听听听听听
About EDAP TMS SA
A recognized leader in robotic energy-based therapies,听EDAP TMS听develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery,听EDAP introduced the Focal听One庐听in听Europe听and in the听U.S.听as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit听.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the 鈥淪ecurities Act鈥�) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as 鈥渂elieve,鈥� 鈥渃an,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥減lan,鈥� 鈥渋ntend,鈥� 鈥渋s designed to,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減otential,鈥� 鈥渙bjective,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥減redict,鈥� 鈥渇orecast,鈥� 鈥渁mbition,鈥� 鈥済uideline,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渆stimate,鈥� 鈥渆xpect鈥� and 鈥渁nticipate,鈥� or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements include our expectations to enter into a credit facility with EIB, the size thereof, the timing thereof and the use of proceeds from such credit facility. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
[email protected]
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | Three Months Ended: | 听 | Three Months Ended: | ||||
| 听 | 听听听听 | June听30,听 | 听听听听 | June听30,听 | 听听听听 | June听30,听 | 听听听听 | June听30,听 |
| 听 | 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 |
| 听 | 听 | Euros | 听 | Euros | 听 | $US | 听 | $US |
| Sales of medical equipment | 听 | 11,221 | 听 | 11,118 | 听 | 12,891 | 听 | 11,948 |
| Net sales of RPP and leases | 听 | 2,246 | 听 | 1,886 | 听 | 2,580 | 听 | 2,027 |
| Sales of spare parts, supplies and services | 听 | 2,576 | 听 | 2,787 | 听 | 2,960 | 听 | 2,995 |
| TOTAL REVENUES | 听 | 16,043 | 听 | 15,791 | 听 | 18,431 | 听 | 16,970 |
| Cost of sales | 听 | (9,221) | 听 | (9,872) | 听 | (10,594) | 听 | (10,609) |
| GROSS PROFIT | 听 | 6,822 | 听 | 5,919 | 听 | 7,838 | 听 | 6,361 |
| Research & development expenses | 听 | (2,208) | 听 | (2,077) | 听 | (2,537) | 听 | (2,232) |
| Selling, general & administrative expenses | 听 | (10,382) | 听 | (9,989) | 听 | (11,928) | 听 | (10,736) |
| Total operating expenses | 听 | (12,591) | 听 | (12,066) | 听 | (14,465) | 听 | (12,967) |
| OPERATING LOSS | 听 | (5,769) | 听 | (6,147) | 听 | (6,628) | 听 | (6,606) |
| Interest (expense) income, net | 听 | (57) | 听 | 190 | 听 | (66) | 听 | 204 |
| Currency exchange gains (loss), net | 听 | 319 | 听 | (49) | 听 | 367 | 听 | (52) |
| LOSS BEFORE INCOME TAXES | 听 | (5,507) | 听 | (6,005) | 听 | (6,327) | 听 | (6,454) |
| Income tax (expense) credit, net | 听 | (93) | 听 | (127) | 听 | (107) | 听 | (136) |
| NET LOSS | 听 | (5,600) | 听 | (6,132) | 听 | (6,434) | 听 | (6,590) |
| Earning per share 鈥� basic and diluted | 听 | (0.15) | 听 | (0.16) | 听 | (0.17) | 听 | (0.18) |
| Average number of shares used in computation of basic and diluted EPS | 听 | 37,420,318 | 听 | 37,205,307 | 听 | 37,420,318 | 听 | 37,205,307 |
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average three months鈥� exchange rate of 1 Euro = 1.1489 USD, and 2024 average three months鈥� exchange rate of 1 Euro = 1.0747 USD
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | Six Months Ended: | 听 | Six Months Ended: | ||||
| 听 | 听听听听 | June听30,听 | 听听听听 | June听30,听 | 听听听听 | June听30,听 | 听听听听 | June听30,听 |
| 听 | 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 |
| 听 | 听 | Euros | 听 | Euros | 听 | $US | 听 | $US |
| Sales of medical equipment | 听 | 20,184 | 听 | 21,085 | 听 | 22,224 | 听 | 22,735 |
| Net sales of RPP and leases | 听 | 4,406 | 听 | 3,661 | 听 | 4,851 | 听 | 3,948 |
| Sales of spare parts, supplies and services | 听 | 5,011 | 听 | 5,952 | 听 | 5,518 | 听 | 6,418 |
| TOTAL REVENUES | 听 | 29,601 | 听 | 30,698 | 听 | 32,593 | 听 | 33,102 |
| Cost of sales | 听 | (17,084) | 听 | (18,394) | 听 | (18,811) | 听 | (19,834) |
| GROSS PROFIT | 听 | 12,517 | 听 | 12,304 | 听 | 13,782 | 听 | 13,267 |
| Research & development expenses | 听 | (4,663) | 听 | (4,146) | 听 | (5,134) | 听 | (4,470) |
| Selling, general & administrative expenses | 听 | (19,619) | 听 | (19,121) | 听 | (21,602) | 听 | (20,618) |
| Total operating expenses | 听 | (24,282) | 听 | (23,267) | 听 | (26,736) | 听 | (25,088) |
| OPERATING LOSS | 听 | (11,765) | 听 | (10,963) | 听 | (12,954) | 听 | (11,821) |
| Interest (expense) income, net | 听 | (43) | 听 | 335 | 听 | (47) | 听 | 361 |
| Currency exchange gains (loss), net | 听 | (637) | 听 | 187 | 听 | (701) | 听 | 202 |
| LOSS BEFORE INCOME TAXES | 听 | (12,444) | 听 | (10,440) | 听 | (13,702) | 听 | (11,258) |
| Income tax (expense) credit, net | 听 | (230) | 听 | (238) | 听 | (253) | 听 | (257) |
| NET LOSS | 听 | (12,674) | 听 | (10,678) | 听 | (13,955) | 听 | (11,514) |
| Earning per share 鈥� basic and diluted | 听 | (0.34) | 听 | (0.29) | 听 | (0.37) | 听 | (0.31) |
| Average number of shares used in computation of basic and diluted EPS | 听 | 37,406,202 | 听 | 37,104,348 | 听 | 37,406,202 | 听 | 37,104,348 |
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average six months鈥� exchange rate of 1 Euro = 1.1011 USD, and 2024 average six months鈥� exchange rate of 1 Euro = 1.0783 USD
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of Euros and U.S. Dollars)
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听听听听 | June听30,听 | 听听听听 | December听31,听 | 听听听听 | June听30,听 | 听听听听 | December听31,听 |
| 听 | 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 |
| 听 | 听 | Euros | 听 | Euros | 听 | $US | 听 | $US |
| Cash, cash equivalents and short-term investments | 听 | 16,265 | 听 | 29,836 | 听 | 19,144 | 听 | 30,883 |
| Accounts receivable, net | 听 | 18,527 | 听 | 20,288 | 听 | 21,806 | 听 | 21,000 |
| Inventory | 听 | 15,531 | 听 | 18,495 | 听 | 18,281 | 听 | 19,143 |
| Other current assets | 听 | 1,157 | 听 | 1,258 | 听 | 1,362 | 听 | 1,302 |
| TOTAL CURRENT ASSETS | 听 | 51,480 | 听 | 69,876 | 听 | 60,593 | 听 | 72,328 |
| Property, plant and equipment, net | 听 | 10,202 | 听 | 10,336 | 听 | 12,009 | 听 | 10,699 |
| Goodwill | 听 | 2,412 | 听 | 2,412 | 听 | 2,839 | 听 | 2,496 |
| Other non-current assets | 听 | 4,248 | 听 | 3,439 | 听 | 5,000 | 听 | 3,560 |
| TOTAL ASSETS | 听 | 68,343 | 听 | 86,063 | 听 | 80,441 | 听 | 89,083 |
| Accounts payable & other accrued liabilities | 听 | 18,549 | 听 | 21,350 | 听 | 21,833 | 听 | 22,099 |
| Deferred revenues, current portion | 听 | 5,898 | 听 | 6,641 | 听 | 6,942 | 听 | 6,874 |
| Short term borrowing | 听 | 6,276 | 听 | 6,243 | 听 | 7,387 | 听 | 6,462 |
| Other current liabilities | 听 | 3,392 | 听 | 3,577 | 听 | 3,993 | 听 | 3,702 |
| TOTAL CURRENT LIABILITIES | 听 | 34,115 | 听 | 37,811 | 听 | 40,154 | 听 | 39,138 |
| Obligations under operating and finance leases non-current | 听 | 1,660 | 听 | 1,939 | 听 | 1,954 | 听 | 2,007 |
| Long-term debt, non-current | 听 | 1,022 | 听 | 2,162 | 听 | 1,203 | 听 | 2,238 |
| Deferred revenues, non-current | 听 | 718 | 听 | 358 | 听 | 845 | 听 | 370 |
| Other long-term liabilities | 听 | 3,006 | 听 | 2,897 | 听 | 3,538 | 听 | 2,999 |
| TOTAL LIABILITIES | 听 | 40,521 | 听 | 45,167 | 听 | 47,694 | 听 | 46,752 |
| TOTAL SHAREHOLDERS鈥橢QUITY | 听 | 27,822 | 听 | 40,896 | 听 | 32,747 | 听 | 42,331 |
| TOTAL LIABILITIES & SHAREHOLDERS鈥� EQUITY | 听 | 68,343 | 听 | 86,063 | 听 | 80,441 | 听 | 89,083 |
NOTE: Translated for convenience of the reader to U.S. dollars at the exchange rate of 1 Euro = 1.1770 USD, on June听30,听2025 and at the exchange rate of 1 Euro = 1.0351 USD, on December听31,听2024.
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of Euros and U.S. Dollars)
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听听听听 | Six Months Ended | 听听听听 | Twelve Months Ended | 听听听听 | Six Months Ended | 听听听听 | Twelve Months Ended |
| 听 | 听 | June听30,听 | 听 | December听31,听 | 听 | June听30,听 | 听 | December听31,听 |
| 听 | 听 | 2025 | 听 | 2024 | 听 | 2025 | 听 | 2024 |
| 听 | 听 | (Euros) | 听 | (Euros) | 听 | ($US) | 听 | ($US) |
| NET INCOME (LOSS) | 听 | (12,674) | 听 | (19,018) | 听 | (13,955) | 听 | (20,520) |
| Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1) | 听 | 2,767 | 听 | 7,395 | 听 | 3,046 | 听 | 7,979 |
| OPERATING CASH FLOW | 听 | (9,907) | 听 | (11,623) | 听 | (10,909) | 听 | (12,541) |
| Increase/Decrease in operating assets and liabilities | 听 | 713 | 听 | (1,961) | 听 | 785 | 听 | (2,116) |
| NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES | 听 | (9,194) | 听 | (13,584) | 听 | (10,123) | 听 | (14,657) |
| Additions to capitalized assets produced by the company and other capital expenditures | 听 | (2,669) | 听 | (4,120) | 听 | (2,939) | 听 | (4,445) |
| NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES | 听 | (2,669) | 听 | (4,120) | 听 | (2,939) | 听 | (4,445) |
| NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES | 听 | (1,096) | 听 | 4,635 | 听 | (1,207) | 听 | 5,001 |
| NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | 听 | (611) | 听 | (566) | 听 | 2,531 | 听 | (3,103) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 听 | (13,571) | 听 | (13,635) | 听 | (11,738) | 听 | (17,204) |
(1) including share based compensation expenses for 775 thousand of Euros for the six months ended June听30, 2025 and 3,283 thousand of Euros for the full year ended December听31,听2024.
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average six months鈥� exchange rate of 1 Euro = 1.1011 USD, and 2024 average twelve months exchange rate of 1 Euro = 1.0790 USD
EDAP TMS S.A.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
six months ended June听30,听2025
(Amounts in thousands of Euros)
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听听听听 | HIFU | 听听听听 | 听听听听 | 听听听听 | ESWL | 听听听听 | 听听听听 | 听听听听 | Distribution | 听听听听 | 听听听听 | 听听听听 | Reconciling | 听听听听 | Total听After | 听听听听 | 听听听听 | 听 |
| 听 | 听 | Division | 听 | 听 | 听 | Division | 听 | 听 | 听 | Division | 听 | 听 | 听 | Items | 听 | Consolidation | 听 | 听 | 听 |
| Sales of medical equipment | 听 | 9,321 | 听 | 听听 | 听 | 681 | 听 | 听听 | 听 | 10,181 | 听 | 听听 | 听 | 鈥� | 听 | 20,184 | 听 | 听听 | 听 |
| Net sales of RPP and leases | 听 | 3,752 | 听 | 听听 | 听 | 538 | 听 | 听听 | 听 | 117 | 听 | 听听 | 听 | 鈥� | 听 | 4,406 | 听 | 听听 | 听 |
| Sales of spare parts, supplies and services | 听 | 1,578 | 听 | 听听 | 听 | 2,069 | 听 | 听听 | 听 | 1,365 | 听 | 听听 | 听 | 鈥� | 听 | 5,011 | 听 | 听听 | 听 |
| TOTAL REVENUES | 听 | 14,650 | 听 | 听听 | 听 | 3,288 | 听 | 听听 | 听 | 11,663 | 听 | 听听 | 听 | 鈥� | 听 | 29,601 | 听 | 听听 | 听 |
| GROSS PROFIT (% of Net Sales) | 听 | 7,339 | 听 | 50.1 | %听听 | 1,468 | 听 | 44.6 | %听听 | 3,710 | 听 | 31.8 | %听听 | 鈥� | 听 | 12,517 | 听 | 42.3 | % |
| Research & development expenses | 听 | (4,254) | 听 | 听听 | 听 | (84) | 听 | 听听 | 听 | (325) | 听 | 听听 | 听 | 鈥� | 听 | (4,663) | 听 | 听听 | 听 |
| Selling, general & administrative expenses | 听 | (13,248) | 听 | 听听 | 听 | (507) | 听 | 听听 | 听 | (4,035) | 听 | 听听 | 听 | (1,828) | 听 | (19,619) | 听 | 听听 | 听 |
| OPERATING PROFIT (LOSS) | 听 | (10,163) | 听 | 听听 | 听 | 876 | 听 | 听听 | 听 | (650) | 听 | 听听 | 听 | (1,828) | 听 | (11,765) | 听 | 听听 | 听 |
Attachment
FAQ
What were EDAP's Q2 2025 HIFU revenue and growth?
How much is the European Investment Bank credit facility for EDAP?
What is EDAP's updated HIFU revenue guidance for 2025?
How many Focal One systems did EDAP place in Q2 2025?
What was EDAP's Q2 2025 net loss per share?
How much cash does EDAP have as of Q2 2025?
